The following information has been compiled from publicly available Sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.

Biolog, Inc., is developing the MicroCard, a microfluidics platform that allows for miniaturization of Biolog's 96-well format by reducing the amount of sample and allowing for rapid inoculation of all 96 wells simultaneously. The MicroCard can be adapted for Biolog's microbiology identification products and its new Phenotype MicroArray technology.

BioModa Inc. has patents pending for the use of tetrakis carboxy phenyl porphine (TCPP) for the screening of pre-cancerous conditions in human tissue. BIOMODA has conducted research showing how to use TCPP staining with automated microscopy and/or flow cytometry to accurately detect cancerous and pre-cancerous conditions in human tissues. The company believes its technology can be used as an economical mass screening test for cancer and pre-cancer. BIOMODA's first product to be introduced will be the Lung Cancer/dysplasia screening test.

Oncogene Science and Bayer Diagnostics are developing the ELISA HER-2/neu Oncoprotein Test to measure levels of HER-2/neu shedding in serum. The test is designed to monitor the progression of metastatic breast cancer. It has been used by breast cancer researchers in the U. S. for several years, and was first described in the Journal of Tumor Marker Oncology in 1991.

Molecular Biology - January 2001
Molecular Biology - December 2000
Molecular Biology - November 2000
Molecular Biology - October 2000
Molecular Biology - September 2000
Molecular Biology - July - August 2000
Molecular Biology - June 2000
Molecular Biology - May 2000
Molecular Biology - April 2000
Molecular Biology - March 2000
Molecular Biology - Febuary 2000
Molecular Biology - January 2000
Molecular Biology - December 1999
Molecular Biology - November 1999
Molecular Biology - October 1999
Molecular Biology - September 1999